Our pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers (select a program to learn more).
1 Colorectal Cancer (CRC), Small Cell Lung Cancer (SCLC), Hepatocellular Carcinoma (HCC) in planning stage. Other indications such as Glioblastoma (GBM) and Solid Tumors (ST) may be considered via Investigator Sponsored Trials.
Pipeline products are under clinical investigation and have not yet been proven to be safe and effective.